<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03489304</url>
  </required_header>
  <id_info>
    <org_study_id>819083</org_study_id>
    <nct_id>NCT03489304</nct_id>
  </id_info>
  <brief_title>Zaleplon in HIV Patients With Depression</brief_title>
  <official_title>A 6-week Open-Label Study of Treatment of Insomnia With Zaleplon in HIV Positive Patients With Comorbid Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In HIV positive patients with sleep onset insomnia and receiving pharmacologic treatment for
      comorbid depression, the proposed study aims to evaluate the impact of zaleplon on sleep
      measures determined by insomnia severity index (ISI) and Epworth sleepiness scale (ESS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An estimated &gt;50% of HIV positive individuals report insomnia. Insomnia and other sleep
      disturbances negatively impact outcomes in this population by contributing to metabolic
      dysfunction, reducing quality of life, and impairing psychosocial functioning. Additionally,
      in HIV depressed populations, insomnia may hinder remission from clinical depression. To
      date, there have been no pharmacotherapeutic studies treating insomnia in this population,
      emphasizing the need to determine whether known hypnotic medications work as effectively in
      HIV positive patients, including those with comorbid depression. Non-benzodiazepine hypnotics
      represent an attractive pharmacotherapy for treatment of insomnia in a depressed population,
      as there are reduced side effects and abuse potential compared to classical benzodiazepines.
      Consequently, an open-label study evaluating zaleplon for insomnia in HIV positive patients
      with comorbid depression warrants further study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2014</start_date>
  <completion_date type="Actual">February 4, 2015</completion_date>
  <primary_completion_date type="Actual">February 4, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>6-week open-label study evaluating zaleplon for insomnia in HIV positive patients with comorbid depression</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insomnia Severity Index (ISI)</measure>
    <time_frame>Measure at 6 weeks</time_frame>
    <description>The Insomnia Severity Index is a validated sleep scale that measures clinical insomnia severity. The total score ranges from 0-28 where higher values indicate increased severity of insomnia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>Measure at 6 weeks</time_frame>
    <description>The Epworth Sleepiness Scale (ESS) is a validated sleep scale that quantifies daytime sleepiness across eight domains. The total score ranges from 0-24 where higher values indicate greater daytime sleepiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptomatology (QIDS)</measure>
    <time_frame>Measure at 6 weeks</time_frame>
    <description>The Quick Inventory of Depressive Symptomatology (QIDS) is a validated mood scale that quantifies depression symptoms. The total score ranges from 0-48, where higher values indicate greater depressive symptoms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Clinical Depression</condition>
  <arm_group>
    <arm_group_label>Zaleplon</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open-label zaleplon 5-10mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zaleplon</intervention_name>
    <description>non-benzodiazepine hypnotic agent</description>
    <arm_group_label>Zaleplon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects aged 18-65 years with a diagnosis of asymptomatic seropositive
             HIV

          2. Principal diagnosis of Major Depressive Disorder or Dysthymic Disorder in accordance
             with DSM-IV criteria, and receiving pharmacologic treatment.

          3. Subject has obtained some subjective benefit from current antidepressant therapy and
             is agreeable to remain on the same medication for the course of this study

          4. Current symptoms of insomnia as determined by a total score of at least 2 on items 4,
             5, and 6 of the HAM-D, and specific complaint of sleep onset insomnia (sleep onset
             latency of at least 1 hour, 3 or more times per week))

          5. Free of sleep medication for at least 2 weeks prior to enrollment (we will not enroll
             any patients who might require weaning off of sedative hypnotic medications in order
             to be eligible for the study)

          6. Ability to understand the requirements of the study and provide informed consent

        Exclusion Criteria:

          1. Significant chronic, systemic illness or significant neurologic disorder, including
             traumatic brain injury

          2. Clinically significant history of liver disease

          3. Psychiatrically unstable patients in the clinical judgment of the investigator as
             indicated by current acute suicidality, current homicidal thoughts, or current
             psychosis

          4. Lifetime history of schizophrenia, schizoaffective disorder, or any psychotic illness

          5. History of substance abuse or dependence over the past 6 months

          6. Currently taking medication to assist with sleep (e.g.,
             Ambien/Zolpidem,Dalmane/Flurazepam, Doral/Quazepam, Halcion/Triazolam,
             Lunesta/Eszopiclone, Prosom/Estazolam, Restoril/Temazepam, Rozerem/Ramelteon,
             Sonata/Zaleplon, Melatonin, Unisom, Benadryl).

          7. Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Kayser, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mood &amp; Anxiety Disorders Research and Treatment Program</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <results_first_submitted>August 22, 2018</results_first_submitted>
  <results_first_submitted_qc>August 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2018</results_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insomnia</keyword>
  <keyword>Zaleplon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zaleplon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zaleplon</title>
          <description>Open-label zaleplon 5-10mg daily
Zaleplon: non-benzodiazepine hypnotic agent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zaleplon</title>
          <description>Open-label zaleplon 5-10mg daily
Zaleplon: non-benzodiazepine hypnotic agent</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insomnia Severity Index (ISI)</title>
        <description>The Insomnia Severity Index is a validated sleep scale that measures clinical insomnia severity. The total score ranges from 0-28 where higher values indicate increased severity of insomnia.</description>
        <time_frame>Measure at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zaleplon</title>
            <description>Open-label zaleplon 5-10mg daily
Zaleplon: non-benzodiazepine hypnotic agent</description>
          </group>
        </group_list>
        <measure>
          <title>Insomnia Severity Index (ISI)</title>
          <description>The Insomnia Severity Index is a validated sleep scale that measures clinical insomnia severity. The total score ranges from 0-28 where higher values indicate increased severity of insomnia.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epworth Sleepiness Scale (ESS)</title>
        <description>The Epworth Sleepiness Scale (ESS) is a validated sleep scale that quantifies daytime sleepiness across eight domains. The total score ranges from 0-24 where higher values indicate greater daytime sleepiness.</description>
        <time_frame>Measure at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zaleplon</title>
            <description>Open-label zaleplon 5-10mg daily
Zaleplon: non-benzodiazepine hypnotic agent</description>
          </group>
        </group_list>
        <measure>
          <title>Epworth Sleepiness Scale (ESS)</title>
          <description>The Epworth Sleepiness Scale (ESS) is a validated sleep scale that quantifies daytime sleepiness across eight domains. The total score ranges from 0-24 where higher values indicate greater daytime sleepiness.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quick Inventory of Depressive Symptomatology (QIDS)</title>
        <description>The Quick Inventory of Depressive Symptomatology (QIDS) is a validated mood scale that quantifies depression symptoms. The total score ranges from 0-48, where higher values indicate greater depressive symptoms.</description>
        <time_frame>Measure at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zaleplon</title>
            <description>Open-label zaleplon 5-10mg daily
Zaleplon: non-benzodiazepine hypnotic agent</description>
          </group>
        </group_list>
        <measure>
          <title>Quick Inventory of Depressive Symptomatology (QIDS)</title>
          <description>The Quick Inventory of Depressive Symptomatology (QIDS) is a validated mood scale that quantifies depression symptoms. The total score ranges from 0-48, where higher values indicate greater depressive symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zaleplon</title>
          <description>Open-label zaleplon 5-10mg daily
Zaleplon: non-benzodiazepine hypnotic agent</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Matthew Kayser</name_or_title>
      <organization>Perelman School of Medicine</organization>
      <phone>215 898 8298</phone>
      <email>kayser@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

